U.S. markets closed

Axcella Health Inc. (AXLA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
5.99+0.26 (+4.54%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Performance Outlook
Previous Close5.73
Open5.68
Bid5.70 x 1000
Ask6.20 x 800
Day's Range5.64 - 6.16
52 Week Range2.25 - 7.73
Volume111,466
Avg. Volume94,848
Market Cap224.87M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.03
Earnings DateNov 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.11
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Axcella Announces IND Clearance for AXA1665, Program Updates and 2021 Milestones
    Business Wire

    Axcella Announces IND Clearance for AXA1665, Program Updates and 2021 Milestones

    Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced clearance of the company’s first investigational new drug (IND) filing and provided an update on its product candidates, research and development activities and expected milestones for 2021.

  • Axcella Announces Upcoming Presentation at J.P. Morgan Healthcare Conference
    Business Wire

    Axcella Announces Upcoming Presentation at J.P. Morgan Healthcare Conference

    Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that management will be presenting at the J.P. Morgan 2021 Healthcare Conference on January 14, 2021 at 10:00 a.m. ET.

  • Where Do Hedge Funds Stand On Axcella Health Inc. (AXLA)?
    Insider Monkey

    Where Do Hedge Funds Stand On Axcella Health Inc. (AXLA)?

    With the third-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the fourth quarter. One of these stocks was Axcella Health Inc. (NASDAQ:AXLA). Is Axcella Health Inc. (NASDAQ:AXLA) a […]